Form 4: Immunovant CEO Sells Shares to Cover Tax Obligations After RSU Vesting

Immunovant CEO Peter Salzmann sold 16,692 shares of common stock to cover tax obligations following the vesting of restricted stock units.

Summary

• Immunovant CEO Peter Salzmann sold 16,692 shares of common stock on November 20, 2024, at a weighted average price of $25.45 per share.
• This sale was triggered by the vesting of 28,204 restricted stock units (RSUs) on November 17, 2024, which were part of a larger grant of 451,264 RSUs from August 17, 2022.
• The sale was mandated by Immunovant's policy to cover tax withholding obligations through a 'sell to cover' transaction, and was not a discretionary sale by Mr. Salzmann.
• The shares were sold in multiple transactions at prices ranging from $24.91 to $25.81 per share.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to executive compensation. It is neither particularly positive nor negative, but is a normal part of company operations.

Industry Context

This is a standard transaction for executives who receive stock-based compensation. It is common for companies to have 'sell to cover' policies to manage tax obligations related to vesting equity.

Comparison to Industry Standards

• Many companies use restricted stock units (RSUs) as part of executive compensation packages.
• It is common practice for companies to implement 'sell to cover' policies to manage tax obligations for employees receiving equity compensation.
• The sale of shares by executives to cover tax obligations is a routine occurrence and is not unusual in the biotech industry.

Stakeholder Impact

• The sale of shares by the CEO may have a minor impact on the stock price, but it is not expected to be significant given the nature of the transaction.

Key Dates

Keywords

Immunovant, Peter Salzmann, stock sale, restricted stock units, RSU, tax obligations, sell to cover, executive transaction